Prurigo Nodularis - Pipeline Insight, 2026

DelveInsight's, "Prurigo Nodularis - Pipeline Insight, 2026" report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Prurigo Nodularis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Prurigo Nodularis: Understanding

Prurigo Nodularis: Overview

Prurigo nodularis (PN) is a chronic inflammatory skin disorder characterized by multiple, firm, flesh-colored to pink, intensely pruritic nodules, most commonly affecting the extensor surfaces of the extremities. It can occur at any age and is frequently associated with other conditions involving cutaneous hypersensitivity, including atopic dermatitis and chronic pruritus of various causes. Diagnosis is primarily clinical, although several dermatological conditions may present with similar features and should be excluded. PN can significantly impair physical and psychological well-being and is often difficult to treat, particularly in advanced cases. Management may therefore require a multimodal approach combining general skin-care measures, pharmacological therapies, and psychological interventions.

The exact pathogenesis of prurigo nodularis (PN) remains incompletely understood, although the chronic itch-scratch cycle is considered a key driver of disease development. Persistent pruritus and repeated scratching, arising from dermatological, systemic, infectious, or neuropsychiatric conditions, contribute to the formation and persistence of PN lesions. PN is characterized by increased sensory innervation, including Merkel cells and papillary dermal nerves, along with altered inflammatory-cell activity, particularly involving eosinophils, mast cells, and neutrophils. The associated pruritus is thought to involve cutaneous neurogenic inflammation mediated by neuropeptides such as substance P and calcitonin gene-related peptide (CGRP), as well as vanilloid receptor 1 (VR-1). Elevated interleukin-31 (IL-31), a potent pruritogenic cytokine produced by T cells, also contributes to the intense itching characteristic of PN. Infectious factors, including hepatitis C, Helicobacter pylori, Strongyloides stercoralis, mycobacteria, and HIV, have also been reported as potential associated triggers.

The pathophysiology of prurigo nodularis (PN) remains incompletely understood, but chronic or recurrent mechanical trauma from persistent scratching and friction is considered a major contributor. Repeated scratching promotes epidermal hyperplasia and skin thickening, leading to the development of pruritic plaques and nodules, often accompanied by lichenification, hyperpigmentation, excoriation, crusting, and, in some cases, secondary bacterial infection. PN lesions show increased dermal nerve fibers, while nerve growth factor (NGF) and its receptor tyrosine kinase A (TrkA) are overexpressed and may promote the release of pruritogenic neuropeptides such as substance P and calcitonin gene-related peptide (CGRP). Reduced intraepidermal nerve fiber density has also been observed and is thought to result from chronic scratching, as nerve density may recover following lesion healing. In addition, evidence indicates an important role for T-helper 2 (Th2)-mediated inflammation, with increased signaling through STAT6 and cytokines such as IL-4, IL-5, and IL-13 contributing to PN pathogenesis.

Prurigo nodularis (PN) is primarily diagnosed clinically based on a history of chronic, severe pruritus accompanied by excoriations and firm, flesh-colored to pink nodules, typically affecting the extensor surfaces. Dermoscopy may aid differentiation from conditions such as hypertrophic lichen planus by identifying characteristic vascular and structural features. Skin biopsy may be considered for atypical, ulcerated, bleeding, or treatment-resistant lesions to exclude other disorders. Because severe pruritus may be associated with underlying systemic conditions, patients should also be evaluated for potential renal, hepatic, thyroid, infectious, malignant, or parasitic causes using appropriate laboratory and diagnostic investigations. Serum IgE levels may also be elevated, particularly in patients with coexisting atopic dermatitis.

Management of prurigo nodularis (PN) requires a multimodal approach aimed at breaking the itch-scratch cycle, addressing underlying causes of pruritus, and managing associated psychological factors. General measures include minimizing scratching by keeping nails short and lesions covered, using protective clothing, maintaining skin hydration with gentle cleansers and emollients, applying soothing antipruritic preparations, maintaining a cool environment, and reducing stress. Topical and intralesional therapies, including potent corticosteroids, intralesional triamcinolone, calcineurin inhibitors, capsaicin, and vitamin D analogs, are commonly used, while antihistamines and leukotriene inhibitors may provide additional symptomatic relief. Phototherapy, including narrowband UVB, PUVA, and excimer light, can improve nodular lesions and pruritus. For severe or refractory disease, systemic immunosuppressants such as cyclosporine, methotrexate, azathioprine, and other agents may be considered based on the individual risk-benefit profile. Other investigational or adjunctive approaches include immunomodulatory agents, antidepressants, opioid-receptor modulators, and neurokinin-1 receptor antagonists, while targeted therapies against pathways such as IL-31 signaling represent an evolving treatment strategy for PN.

"Prurigo Nodularis- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Prurigo Nodularis pipeline landscape is provided which includes the disease overview and Prurigo Nodularis treatment guidelines. The assessment part of the report embraces, in depth Prurigo Nodularis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Prurigo Nodularis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Prurigo Nodularis R&D. The therapies under development are focused on novel approaches to treat/improve Prurigo Nodularis.

Prurigo Nodularis Emerging Drugs Chapters

This segment of the Prurigo Nodularis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Prurigo Nodularis Emerging Drugs

Povorcitinib: Incyte Corporation

Povorcitinib (INCB54707) is an orally administered, selective small-molecule Janus kinase 1 (JAK1) inhibitor being evaluated across multiple inflammatory and immune-mediated dermatological and respiratory conditions. The therapy is currently undergoing Phase III clinical development in moderate-to-severe hidradenitis suppurativa (HS) through the STOP-HS1, STOP-HS2, and STOP-HS LTE studies, nonsegmental vitiligo through the STOP-V1 and STOP-V2 studies, and prurigo nodularis (PN) through the STOP-PN1 and STOP-PN2 studies. In addition, povorcitinib is being investigated in a Phase II study for moderate-to-severe asthma, highlighting its potential utility across diseases driven by dysregulated immune and inflammatory pathways. The ongoing Phase III program is expected to provide important evidence regarding its efficacy, safety, durability of response, and potential role in the treatment of these chronic conditions, with topline data for vitiligo anticipated in mid-2026 and for PN in 4th quarter of 2026.

Barzolvolimab: Celldex Therapeutics

Barzolvolimab is a humanized monoclonal antibody that selectively targets the KIT receptor, a key regulator of mast-cell function and survival, by binding to a unique site on KIT and potently inhibiting its activity. By depleting and suppressing mast cells, barzolvolimab is designed to modulate inflammatory responses implicated in hypersensitivity and allergic conditions, including chronic urticarias. Currently, the drug is in Phase II stage of its development for the treatment of Prurigo Nodularis.

CMAB016: Mabpharm Limitied

CMAB016 is an investigational biosimilar candidate to Dupixent(R) (dupilumab) being developed by Mabpharm. It is a fully humanized IgG4 monoclonal antibody that targets the IL-4 receptor alpha (IL-4Ra) subunit, thereby blocking signaling mediated by both IL-4 and IL-13, two key cytokines involved in Type 2 inflammation. Dupilumab is established across several Type 2 inflammatory diseases, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, COPD, and prurigo nodularis (PN). For CMAB016 specifically, Mabpharm has completed engineering cell-line construction, screening, and laboratory-scale process development; the company previously stated plans to complete preclinical studies and submit a clinical trial application in second quarter of 2026, with potential NMPA marketing approval targeted for second quarter of 2029. Currently, the drug is in Preclinical stage of its development for the treatment of Prurigo Nodularis.

Prurigo Nodularis: Therapeutic Assessment

This segment of the report provides insights about the different Prurigo Nodularis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Prurigo Nodularis
• There are approx. 12+ key companies which are developing the therapies for Prurigo Nodularis. The companies which have their Prurigo Nodularis drug candidates in the most advanced stage, i.e. Phase III include, Incyte Corporation.
• Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Prurigo Nodularis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Prurigo Nodularis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Prurigo Nodularis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Prurigo Nodularis drugs.

Prurigo Nodularis Report Insights

• Prurigo Nodularis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Prurigo Nodularis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Prurigo Nodularis drugs?
• How many Prurigo Nodularis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Prurigo Nodularis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Prurigo Nodularis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Prurigo Nodularis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Incyte Corporation
• Celldex Therapeutics
• Beijing InnoCare Pharma
• Shanghai Hengrui Pharmaceutical
• Mabpharm Limitied
• BeOne Medicines
• Roche

Key Products

• Povorcitinib
• barzolvolimab
• Soficitinib
• SHR-1819
• CMAB016
• BGB-45035
• Vixarelimab